By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
The structure of an enzyme class known as enoyl-CoA carboxylases/reductases is revealed via biomolecular imaging. These photosynthesis-related enzymes are incredibly efficient at removing carbon dioxide from the environment by fixing it.
It is now possible to see, characterise, and measure the biological processes occurring at the cellular and subcellular levels in intact living beings, including patients, thanks to the expanding biomedical research field known as molecular imaging (MI).
Molecular imaging procedures are used to diagnose and treat a variety of conditions, including cancer, heart disease, brain disorders like Alzheimer’s and Parkinson’s disease, gastrointestinal disorders, lung disorders, bone disorders, kidney and thyroid disorders, and more. These procedures are noninvasive, safe, and painless.
The Global biomolecular imaging system market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
New Molecular Imaging Systems Are Available From GE Healthcare, Supporting Quantitative Care and Research The Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2016 saw the introduction of new molecular imaging technologies from GE Healthcare that will allow doctors to provide patients with individualised, quantified data.
With the use of the Discovery MI system and Discovery NM/CT 670 CZT, physicians will be better able to direct patient care, provide sensitive support for patients, and foster an environment conducive to compelling research.
The future generation of molecular imaging systems are represented by both systems’ cutting-edge, innovative digital detectors. The new nuclear medicine workstation, XelerisTM 4.0, supports the Discovery NM/CT 670 CZT as well as other nuclear medicine systems.
With its quantitative applications, Xeleris 4.0 gives clinicians greater confidence in their ability to customise and easily read reports for a variety of care settings.
Discovery MI was developed to support doctors in their ongoing attempts to stage diseases early, diagnose patients, and better direct treatment methods. It also enables more compelling research using a wider variety of innovative, quickly degrading tracers.
The only PET/CT system in the market, Discovery MI combines the most cutting-edge reconstruction technology—the union of Time-of-Flight (TOF) and Q.Clear—with the sensitivity of digital detection. Outstanding resolution improves the ability to find small lesions as a result.
Due to the system’s wider range of view, clinicians will be able to conduct more interesting research, such as quantitative brain tests (FOV).
Discovery MI may also broaden the range of diagnostic services that doctors may provide by improving their cancer clinical expertise or by pushing the limits of PET in areas such as neurology, cardiology, and other fields. These increased powers
